Tirzepatide 5mg
All products are 100% genuine and sourced from trusted manufacturers, with authenticity that can be verified for complete peace of mind.
Order exactly what you need with no minimum quantity required, whether it’s a single unit or a larger order.
Your order is guaranteed to arrive safely, with full shipment tracking and dedicated support to ensure a smooth delivery experience.
Your payments are protected with industry-standard encryption and trusted payment providers, ensuring every transaction is safe, private, and secure.
99% PURITY GUARANTEE
99% PURITY GUARANTEE
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC). Full analytical reports are available in the Certificate of Analysis section.
Preparation & Handling Notice
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
RESEARCH USE ONLY
This product is intended for research use only. It is not for human or veterinary use, not for diagnostic or therapeutic purposes, and should only be handled by qualified professionals.
Strength: 5 mg
CAS: 2023788-19-2
Chemical Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight: 4813.48 g/mol
Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.
Tirzepatide, also known as LY3298176 or P1206, is a synthetic dual receptor–targeted peptide supplied as a high-purity lyophilized powder for laboratory research. It is widely studied in metabolic and endocrine research models to investigate hormone receptor signaling, glucose regulation pathways, and energy balance mechanisms under controlled experimental conditions.
-
Cold chain shipping available for temperature-sensitive products.
-
Orders are processed within 1–2 business days.
-
Delivery timelines vary by destination and shipping method — view our Shipping Policy for region-specific estimates.
-
Tracking information will be provided once shipped.
-
No order minimum applies.
-
If your shipment is delayed, lost, or arrives damaged, you're covered under our Refund & Replacement Policy.
We accept Visa, Mastercard, and American Express. Apple Pay and Google Pay are available upon request via your account manager.
All transactions are processed through a secure, PCI DSS–compliant system to ensure your data is fully protected.
Why Choose NOVERA COMPOUNDS Peptides?
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
- High-purity, research-grade peptide synthesis
- Analytical testing to verify quality and composition
- Consistent batch-to-batch performance
- Batch identification on every vial for traceability
- Stored and shipped under controlled conditions
High-purity, research-grade peptide synthesis
Why Choose Medica Depot
Shop hundreds of medical products with no minimums and free shipping on large orders.
400+ products
No order minimums
Free shipping
Loyalty rewards
Trusted since 2007
Account manager
Verified LOT numbers
INFORMATION
What is Tirzepatide (5 mg)?
Tirzepatide (5 mg) is a sequence-defined, modified peptide used in laboratory research to explore incretin-related signaling and its downstream cellular effects. It is engineered to activate both the GIP receptor and GLP-1 receptor, making it a valuable tool for studying receptor activation patterns, pathway “cross-talk,” and metabolic signaling responses in experimental models.
The peptide is further modified with a fatty diacid moiety (via a linker), which is commonly evaluated in research on peptide stability, distribution behavior, and extended exposure profiles.
Product Specifications
- Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
- CAS Number: 2023788-19-2
- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight:48 g/mol
- Peptide Sequence:
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ - Purity: ≥95% (verified by HPLC and mass spectrometry)
- Packaging Format: 5 mg lyophilized powder in a sealed research-grade vial
- Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
- Intended Use: For Laboratory Research Use Only
Key Characteristics of Tirzepatide (5 mg)
- Dual-receptor research tool: Ideal for studies comparing GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) signaling and their shared downstream pathways.
- Defined chemical identity: Ensures reproducible documentation and consistency across experimental studies.
- Fatty-diacid conjugation: Relevant in experiments investigating peptide design, such as albumin association and extended exposure profiles.
- Standard laboratory handling: Requires cold, light-protected storage before reconstitution to support research applications.
How Tirzepatide (5 mg) Supports Research
In controlled laboratory experiments, Tirzepatide (5 mg) is used to investigate incretin receptor activation and to track downstream effects, including cAMP activation, pathway-selective responses, and comparative receptor pharmacology. Researchers also use this peptide to study how structural modifications, such as lipid conjugation, influence peptide behavior and activity in experimental systems.
Research Applications & Usage Information
Tirzepatide (5 mg) is commonly used in laboratory research for:
- Receptor pharmacology studies: Characterizing agonist activity at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) in cell-based assays.
- Metabolic signaling research: Mapping pathways related to glucose-sensing and nutrient-response biology (readouts may vary by model).
- Comparative incretin research: Evaluating Tirzepatide side-by-side with selective GLP-1 pathway tools in mechanistic study designs.
- Peptide engineering and pharmacokinetic studies: Investigating the effects of lipidation and other peptide modifications on exposure profiles.
Handling and Storage Recommendations
- Store at -20°C (or 2–8°C for short-term storage). Protect from light exposure.
- Avoid repeated freeze-thaw cycles to support research applications.
- Keep the vial tightly sealed and use proper laboratory techniques to prevent contamination.
- Follow all relevant chemical hygiene protocols, labeling requirements, and disposal procedures.
Research Use Only Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
- Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
What is Tirzepatide (5 mg)?
Tirzepatide (5 mg) is a sequence-defined, modified peptide used in laboratory research to explore incretin-related signaling and its downstream cellular effects. It is engineered to activate both the GIP receptor and GLP-1 receptor, making it a valuable tool for studying receptor activation patterns, pathway “cross-talk,” and metabolic signaling responses in experimental models.
The peptide is further modified with a fatty diacid moiety (via a linker), which is commonly evaluated in research on peptide stability, distribution behavior, and extended exposure profiles.
Product Specifications
- Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
- CAS Number: 2023788-19-2
- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight:48 g/mol
- Peptide Sequence:
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ - Purity: ≥95% (verified by HPLC and mass spectrometry)
- Packaging Format: 5 mg lyophilized powder in a sealed research-grade vial
- Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
- Intended Use: For Laboratory Research Use Only
Key Characteristics of Tirzepatide (5 mg)
- Dual-receptor research tool: Ideal for studies comparing GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) signaling and their shared downstream pathways.
- Defined chemical identity: Ensures reproducible documentation and consistency across experimental studies.
- Fatty-diacid conjugation: Relevant in experiments investigating peptide design, such as albumin association and extended exposure profiles.
- Standard laboratory handling: Requires cold, light-protected storage before reconstitution to support research applications.
How Tirzepatide (5 mg) Supports Research
In controlled laboratory experiments, Tirzepatide (5 mg) is used to investigate incretin receptor activation and to track downstream effects, including cAMP activation, pathway-selective responses, and comparative receptor pharmacology. Researchers also use this peptide to study how structural modifications, such as lipid conjugation, influence peptide behavior and activity in experimental systems.
Research Applications & Usage Information
Tirzepatide (5 mg) is commonly used in laboratory research for:
- Receptor pharmacology studies: Characterizing agonist activity at the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) in cell-based assays.
- Metabolic signaling research: Mapping pathways related to glucose-sensing and nutrient-response biology (readouts may vary by model).
- Comparative incretin research: Evaluating Tirzepatide side-by-side with selective GLP-1 pathway tools in mechanistic study designs.
- Peptide engineering and pharmacokinetic studies: Investigating the effects of lipidation and other peptide modifications on exposure profiles.
Handling and Storage Recommendations
- Store at -20°C (or 2–8°C for short-term storage). Protect from light exposure.
- Avoid repeated freeze-thaw cycles to support research applications.
- Keep the vial tightly sealed and use proper laboratory techniques to prevent contamination.
- Follow all relevant chemical hygiene protocols, labeling requirements, and disposal procedures.
Research Use Only Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
- Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009
Related products
